BioTime Inc. (BTX)

1.17
0.03 2.50
AMEX : Health Technology
Prev Close 1.20
Open 1.20
Day Low/High 1.13 / 1.20
52 Wk Low/High 0.66 / 2.81
Volume 192.41K
Avg Volume 494.00K
Exchange AMEX
Shares Outstanding 149.64M
Market Cap 169.10M
EPS -0.40
P/E Ratio 2.83
Div & Yield N.A. (N.A)

Latest News

BioTime Announces Appointment Of General Counsel

BioTime Announces Appointment Of General Counsel

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has appointed Chase C.

BioTime Awarded $2.5 Million Grant From The Israel Innovation Authority For Continued Development Of OpRegen®

BioTime Awarded $2.5 Million Grant From The Israel Innovation Authority For Continued Development Of OpRegen®

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels (approximately...

BioTime Reports First Quarter 2019 Financial Results And Provides Business Update

BioTime Reports First Quarter 2019 Financial Results And Provides Business Update

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, reported financial and operating results for the first quarter ended March 31, 2019.

BioTime Announces Issuance Of U.S. Patent For Method Of Reducing Cavitation In Patients With Acute Spinal Cord Injury

BioTime Announces Issuance Of U.S. Patent For Method Of Reducing Cavitation In Patients With Acute Spinal Cord Injury

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office...

BioTime To Report First Quarter 2019 Financial Results And Provide Business Update On May 9, 2019

BioTime To Report First Quarter 2019 Financial Results And Provide Business Update On May 9, 2019

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that it will report its first quarter 2019 financial and operating results on Thursday, May 9 th, 2019, following the...

BioTime Presents Updated Data From OpRegen® Phase I/IIa Clinical Study At The Association For Research In Vision And Ophthalmology Annual Meeting

BioTime Presents Updated Data From OpRegen® Phase I/IIa Clinical Study At The Association For Research In Vision And Ophthalmology Annual Meeting

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen ®, a retinal pigment epithelium...

BioTime To Present SCiStar Clinical Study Top-Line Data At The 26th Annual American Society For Neural Therapy And Repair Conference

BioTime To Present SCiStar Clinical Study Top-Line Data At The 26th Annual American Society For Neural Therapy And Repair Conference

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that Edward D.

BioTime To Present Data From OpRegen® Phase I/IIa Clinical Study At The Association For Research In Vision And Ophthalmology Annual Meeting (ARVO 2019)

BioTime To Present Data From OpRegen® Phase I/IIa Clinical Study At The Association For Research In Vision And Ophthalmology Annual Meeting (ARVO 2019)

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen ®, a retinal pigment...

BioTime To Present At Oppenheimer & Co. 29th Annual Healthcare Conference On March 20, 2019

BioTime To Present At Oppenheimer & Co. 29th Annual Healthcare Conference On March 20, 2019

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M.

BioTime Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update

BioTime Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating results for the fourth quarter and full year ended December 31, 2018.

BioTime Announces Closing Of Acquisition Of Asterias Biotherapeutics Creating Leading Cell Therapy Company

BioTime Announces Closing Of Acquisition Of Asterias Biotherapeutics Creating Leading Cell Therapy Company

BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported acquisition of Asterias Biotherapeutics, Inc.

BioTime To Report Fourth Quarter And Full Year 2018 Financial Results On March 14th, 2019

BioTime To Report Fourth Quarter And Full Year 2018 Financial Results On March 14th, 2019

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its fourth quarter and full year 2018 financial and operating results on Thursday, March 14 th, 2019,...

BioTime To Present At The 14Th Annual Scientific Meeting Of The Association For Ocular Pharmacology And Therapeutics (AOPT 2019) On March 10, 2019

BioTime To Present At The 14Th Annual Scientific Meeting Of The Association For Ocular Pharmacology And Therapeutics (AOPT 2019) On March 10, 2019

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that Francois Binette, PhD, Senior Vice President and Global Head of Product Development at BioTime, Inc.

AgeX Therapeutics Publishes Data In Peer-Reviewed Journal To Advance Potential Cell Therapy AgeX-BAT1 For Type II Diabetes And Obesity

AgeX Therapeutics Publishes Data In Peer-Reviewed Journal To Advance Potential Cell Therapy AgeX-BAT1 For Type II Diabetes And Obesity

AgeX Therapeutics, Inc. (NYSE American: AGE) announced today the publication of data relating to its cell therapy product candidate AgeX-BAT1 for Type II diabetes and obesity in the peer-reviewed scientific journal Stem Cell Research & Therapy.

BioTime To Present At 2019 Biotech Showcase Investor Conference On January 7, 2019

BioTime To Present At 2019 Biotech Showcase Investor Conference On January 7, 2019

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M.

AgeX Therapeutics To Present At Biotech Showcase 2019

AgeX Therapeutics To Present At Biotech Showcase 2019

AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at  Biotech Showcase, to be held January 7-9, 2019 in San...

BioTime Announces Publication Of Positive Preclinical Results Utilizing Proprietary HyStem® Platform In Ischemic Stroke

BioTime Announces Publication Of Positive Preclinical Results Utilizing Proprietary HyStem® Platform In Ischemic Stroke

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the publication of positive preclinical results which demonstrate that targeted intracerebral delivery of brain-derived...

BioTime To Present At The LD Micro 11th Annual Main Event Investor Conference On December 5th, 2018

BioTime To Present At The LD Micro 11th Annual Main Event Investor Conference On December 5th, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M.

AgeX Therapeutics, Inc. To Present Keynote Address At Advanced Stem Cell & Regenerative Medicine 2018 Conference

AgeX Therapeutics, Inc. To Present Keynote Address At Advanced Stem Cell & Regenerative Medicine 2018 Conference

AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D.

AgeX Therapeutics, Inc. Shares Commence Trading On The NYSE American

AgeX Therapeutics, Inc. Shares Commence Trading On The NYSE American

AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced today that its common stock is now trading on the NYSE American exchange under the...

BioTime Announces Distribution Of AgeX Therapeutics Shares

BioTime Announces Distribution Of AgeX Therapeutics Shares

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that the registration statement on Form 10, including the information statement relating to the distribution that was...

BioTime And Asterias Biotherapeutics Enter Into Definitive Merger Agreement To Create Leading Cell Therapy Company

BioTime And Asterias Biotherapeutics Enter Into Definitive Merger Agreement To Create Leading Cell Therapy Company

BioTime, Inc. (NYSE American and TASE: BTX), and Asterias Biotherapeutics, Inc.

BioTime Reports Third Quarter 2018 Financial Results And Provides Business Update

BioTime Reports Third Quarter 2018 Financial Results And Provides Business Update

BioTime, Inc. (NYSE American:BTX), a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating results for the third quarter ended September 30, 2018.

BioTime Announces Update To Third Quarter 2018 Financial Results Conference Call

BioTime Announces Update To Third Quarter 2018 Financial Results Conference Call

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has changed the time of its previously announced conference call to discuss its third quarter 2018 financial and...

BioTime Receives Second Installment Payment Of $10.8 Million From Juvenescence Ltd.

BioTime Receives Second Installment Payment Of $10.8 Million From Juvenescence Ltd.

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has received the second installment payment of $10.

BioTime To Report Third Quarter 2018 Financial Results On November 8th, 2018

BioTime To Report Third Quarter 2018 Financial Results On November 8th, 2018

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its third quarter 2018 financial and operating results on Thursday, November 8 th, 2018, following...

BioTime Presents New OpRegen® Data At American Academy Of Ophthalmology Annual Meeting

BioTime Presents New OpRegen® Data At American Academy Of Ophthalmology Annual Meeting

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced positive additional results from an ongoing Phase I/IIa study of its lead product candidate, OpRegen ®, a retinal pigment...

BioTime Announces November 16, 2018 Record Date And November 28, 2018 Distribution Date For The Distribution Of Age-X Therapeutics Shares

BioTime Announces November 16, 2018 Record Date And November 28, 2018 Distribution Date For The Distribution Of Age-X Therapeutics Shares

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the record date for and distribution date for the distribution of AgeX Therapeutics ("AgeX")...

TheStreet Quant Rating: D+ (Sell)